History
Bromo-DragonFLY was first synthesized by Matthew A. Parker in the laboratory of David E. Nichols in 1998.
Pharmacology
The hallucinogenic effect of bromo-DragonFLY is mediated by its agonist activity at the 5-HT2A serotonin receptor. Bromo-DragonFLY also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptors.
Dosage
The typical dose of Bromo-DragonFLY is not known, however it has varied from 500 ?g to 1 mg.[1] It has about 300 times the potency of mescaline, or 1/5th the potency of LSD. It has been sold in the form of blotters, similar to the distribution method of LSD, which has led to confusion, and reports of mistakenly consuming Bromo-DragonFly. It has a much longer duration of action than LSD and can last for up to 2-3 days[1] following a single large dose, with a slow onset of action that can take up to 6 hours before the effects are felt.
Toxicity
The toxicity of Bromo-DragonFLY is unknown for humans however at least three reports of death believed to be resulted from Bromo-DragonFLY have been reported in Norway[3], Sweden[4] and Denmark[5]
Also, a Swedish man had to have the front part of his feet and several fingers on one hand amputated after taking a massive overdose. Apparently the compound acted as a long-acting efficacious vasoconstrictor, leading to necrosis and gangrene which was delayed by several weeks after the overdose occurred. Several other cases have also been reported of severe peripheral vasoconstriction following overdose with Bromo-DragonFLY, and a similar case is also known from DOB. Treatment was of limited efficacy in this case although tolazoline is reportedly an effective treatment where available.[6][7]
Overdoses, disturbing experiences, and Bromo-DragonFLY associated health problems have been described. One case in 2008 in England involved inhalation of vomit, causing nearly fatal asphyxia.[8]